Internal Medicine, Endocrinology, Diabetes, & Metabolism · New York, NY
NPI
1467615823
Since 2008
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
160 E 32nd St
New York, NY, 10016
Phone (212) 675-9332
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
26,222 services
Medicare patients, 2024
1,331
Average age 73
Drug cost, 2024
$6.9M
12,876 prescriptions
Company payments, 2025
$175K
From 34 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anastasios Manessis was code 99457 (e&m - miscellaneous), 2,215 times for 486 patients. In total Anastasios Manessis billed 26,222 services in 119 codes, and Medicare paid $1.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-01-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99457 E&M - Miscellaneous | Office | 2,215 | 486 | $43.89 | $97K |
| 99454 E&M - Miscellaneous | Office | 2,126 | 341 | $45.55 | $97K |
| 99424 Chronic, Principal, and Transitional Care Management | Office | 1,796 | 485 | $76.04 | $137K |
| 99213 Office E&M - Established | Office | 1,442 | 696 | $81.36 | $117K |
| 84443 Clinical Chemistry | Office | 1,234 | 765 | $16.42 | $20K |
| 36415 Venipuncture Blood Collection | Office | 1,229 | 722 | $8.63 | $11K |
| 84439 Clinical Chemistry | Office | 1,224 | 762 | $8.84 | $11K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,215 | 320 | $52.52 | $64K |
| 99214 Office E&M - Established | Office | 1,084 | 620 | $112.60 | $122K |
| 83036 Blood Count | Office | 1,056 | 628 | $9.48 | $10K |
| 83735 Clinical Chemistry | Office | 1,041 | 645 | $6.57 | $6,839 |
| 84100 Clinical Chemistry | Office | 1,004 | 625 | $4.65 | $4,669 |
| 85025 Blood Count | Office | 993 | 613 | $7.59 | $7,540 |
| 80061 Clinical Chemistry | Office | 982 | 605 | $13.09 | $13K |
| 80076 Clinical Chemistry | Office | 934 | 580 | $8.01 | $7,481 |
By year: 2022 $710K for 22,173 services; 2023 $924K for 23,476 services; 2024 $1.1M for 26,222 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 84443 Clinical Chemistry | 1,234 | 765 | $16.42 | $20K |
| 36415 Venipuncture Blood Collection | 1,229 | 722 | $8.63 | $11K |
| 84439 Clinical Chemistry | 1,224 | 762 | $8.84 | $11K |
| 83036 Blood Count | 1,056 | 628 | $9.48 | $10K |
| 83735 Clinical Chemistry | 1,041 | 645 | $6.57 | $6,839 |
| 84100 Clinical Chemistry | 1,004 | 625 | $4.65 | $4,669 |
| 85025 Blood Count | 993 | 613 | $7.59 | $7,540 |
| 80061 Clinical Chemistry | 982 | 605 | $13.09 | $13K |
| 80076 Clinical Chemistry | 934 | 580 | $8.01 | $7,481 |
| 80048 Clinical Chemistry | 682 | 484 | $8.29 | $5,654 |
Medicare prescription drug claims, 2024
In 2024, the drug Anastasios Manessis prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 1,281 prescriptions and refills. In total Anastasios Manessis wrote 12,876 Medicare prescriptions that cost $6.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 1,281 | 1,615 | 256 | $1.7M |
| Levothyroxine Sodium Generic | 803 | 2,086 | 257 | $9,729 |
| Ozempic Semaglutide | 792 | 1,157 | 194 | $1.1M |
| Jardiance Empagliflozin | 704 | 1,350 | 197 | $778K |
| Metformin Hcl Generic | 667 | 1,757 | 235 | $11K |
| Metformin Hcl Er Metformin Hcl | 475 | 1,243 | 169 | $6,465 |
| Farxiga Dapagliflozin Propanediol | 440 | 864 | 121 | $470K |
| Synthroid Levothyroxine Sodium | 381 | 1,005 | 125 | $38K |
| Tresiba Flextouch U-100 Insulin Degludec | 365 | 811 | 128 | $242K |
| Atorvastatin Calcium Generic | 344 | 926 | 123 | $3,232 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 321 | 884 | 155 | $42K |
| Trulicity Dulaglutide | 267 | 400 | 71 | $382K |
| Novolog Flexpen Insulin Aspart | 247 | 501 | 89 | $56K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 223 | 489 | 81 | $29K |
| Humalog Kwikpen U-100 Insulin Lispro | 197 | 433 | 63 | $59K |
Brand drugs: 7,086 claims; generic drugs: 4,696 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anastasios Manessis $175K ($175K in general payments such as food, travel and fees) from 34 companies. The largest payer was Ascendis Pharma Endocrinology Inc with $62K.
| Company | Payments | Amount |
|---|---|---|
| Ascendis Pharma Endocrinology Inc ASND | 65 | $62K |
| Lilly USA, LLC LLY | 74 | $42K |
| Novo Nordisk Inc NVO | 53 | $34K |
| Sanofi-Aventis U.S. LLC SNY | 13 | $20K |
| Amgen Inc. AMGN | 16 | $7,308 |
| Corcept Therapeutics CORT | 20 | $2,880 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $1,794 |
| Mannkind Corporation MNKD | 10 | $1,778 |
| Abbott Laboratories ABT | 12 | $471 |
| Xeris Pharmaceuticals, Inc. | 17 | $286 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.